Table 2.
Ilixadencel treatment line including doses of ilixadencel for each participant in each group
| Patient | Years (age) | Sex | Primary tumor site | Mutation in primary tumor | Site of disease | ECOG |
|---|---|---|---|---|---|---|
| 1 | 46 | M | Small intestine | KIT Exon 9 | Abdominal cavity | 0 |
| 3 | 59 | M | Small intestine | KIT Exon 9 | Abdominal cavity | 2 |
| 4 | 56 | F | ND | No mutation in KIT or PDGFRA | Abdominal cavity, liver, cutaneous | 0 |
| 5 | 51 | F | Small intestine | KIT Exon 9 | Peritoneal, liver, lymph | 1 |
| 6 | 50 | M | ND | KIT Exon 11 | Abdominal cavity | 0 |
| 7 | 82 | F | Small intestine | KIT Exon 11 | Abdominal cavity, liver | 1 |
M male, F female, ND not determined